Reported Reactions

Adverse event reports that FDA received

  • Search
  • Watch list

Prothrombin time prolonged adverse event reports that record this term

Kind of term
MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on . The data have the reports that FDA received through .

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on .

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 5,893 adverse event reports that record the MedDRA preferred term Prothrombin time prolonged. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 121 reports in the 12 months to June 2026 and 172 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,366 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 121 (under 0.1%) record this term. Reports for patients 75 and over were 21.5% of the reports that record this term and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 58 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Drugs that the reports with the term Prothrombin time prolonged name as a suspect product, in order of name
DrugClassReports with this term
Acetaminophen179
Acetylsalicylic Acid41
Amiodarone27
Apap39
ApixabanFactor Xa inhibitor33
AspirinNonsteroidal anti-inflammatory drug158
AvastinVascular endothelial growth factor inhibitor25
BevacizumabVascular endothelial growth factor inhibitor29
CapecitabineNucleoside metabolic inhibitor25
CarboplatinPlatinum-based drug35
CiprofloxacinFluoroquinolone antibacterial34
CisplatinPlatinum-based drug35
ClopidogrelP2Y12 platelet inhibitor26
Coumadin278
CroFab26
CyclophosphamideAlkylating drug63
CytarabineNucleoside metabolic inhibitor62
DexamethasoneCorticosteroid78
Diclofenac sodiumNonsteroidal anti-inflammatory drug33
DigoxinCardiac glycoside81
EliquisFactor Xa inhibitor57
Enoxaparin sodiumLow molecular weight heparin39
EtoposideTopoisomerase inhibitor28
FluorouracilNucleoside metabolic inhibitor35
FurosemideLoop diuretic32
GabapentinAnti-epileptic agent25
Heparin27
Humira26
IbuprofenNonsteroidal anti-inflammatory drug82
Ketek26
LovenoxLow molecular weight heparin33
Marcumar49
MethotrexateFolate analog metabolic inhibitor92
MethylprednisoloneCorticosteroid25
OxaliplatinPlatinum-based drug26
Paracetamol49
PlavixP2Y12 platelet inhibitor26
PradaxaDirect thrombin inhibitor170
PrednisoloneCorticosteroid35
PrednisoneCorticosteroid60
RamiprilAngiotensin converting enzyme inhibitor31
RevlimidThalidomide analog43
RibavirinNucleoside analog antiviral32
Rifampicin26
RivaroxabanFactor Xa inhibitor53
Sintrom39
Thalomid35
TracleerEndothelin receptor antagonist31
TylenolExpectorant35
TYLENOL Extra Strength25
VelcadeProteasome inhibitor32
Vincristine sulfateVinca alkaloid44
WarfarinVitamin K antagonist251
Warfarin sodiumVitamin K antagonist259
XareltoFactor Xa inhibitor292
XelodaNucleoside metabolic inhibitor27
Xigris55
Zometa36

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 46 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Pharmacologic classes of the drugs that the reports with the term Prothrombin time prolonged name, in order of name
ClassReports with this term
Alkylating drug92
Angiotensin 2 receptor blocker31
Angiotensin converting enzyme inhibitor42
Anthracycline topoisomerase inhibitor40
Anti-coagulant28
Anti-epileptic agent111
Antimycobacterial31
Aromatase inhibitor27
Atypical antipsychotic79
Azole antifungal32
Benzodiazepine48
beta-Adrenergic blocker51
Biguanide34
Calcineurin inhibitor immunosuppressant37
Cardiac glycoside81
Cephalosporin antibacterial44
Corticosteroid212
Direct thrombin inhibitor176
Endothelin receptor antagonist58
Expectorant35
Factor Xa inhibitor457
Fluoroquinolone antibacterial57
Folate analog metabolic inhibitor103
Histamine-1 receptor antagonist36
HMG-CoA reductase inhibitor66
Iron chelator27
Kinase inhibitor131
Loop diuretic56
Low molecular weight heparin72
Microtubule inhibitor31
Nonsteroidal anti-inflammatory drug322
Nucleoside analog antiviral32
Nucleoside metabolic inhibitor212
Opioid agonist99
P2Y12 platelet inhibitor74
Platinum-based drug96
Proteasome inhibitor37
Proton pump inhibitor47
Serotonin reuptake inhibitor78
Tetracycline-class antibacterial31
Thalidomide analog43
Topoisomerase inhibitor36
Tumor necrosis factor blocker34
Vascular endothelial growth factor inhibitor54
Vinca alkaloid50
Vitamin K antagonist510

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Prothrombin time prolonged, by month, five years to June 2026
0255020222023202420252026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Prothrombin time prolonged
AgeReportsShareShare as a bar
Under 2931.6%
2 to 111482.5%
12 to 171883.2%
18 to 4480813.7%
45 to 641,30322.1%
65 to 7494216%
75 and over1,26621.5%
Age not given1,14519.4%
Sex of the patient in the reports that record Prothrombin time prolonged
SexReportsShareShare as a bar
Female2,75646.8%
Male2,72946.3%
Unknown or not given4086.9%

Age and sex are as the report gives them. 41.8% of these reports give the United States as the country.

Terms near this one

Official pages

The site checked these addresses on . The links open in a new tab.

Cite this page

Reported Reactions. Prothrombin time prolonged: adverse event reports that record this term. https://reportedreactions.com/reaction/prothrombin-time-prolonged/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of . Reports received through .

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Prothrombin time prolonged mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.

Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on .